Growth factor receptor interplay and resistance in cancer.
about
Mechanisms of resistance to anti-EGFR therapy in colorectal cancerLevels of active tyrosine kinase receptor determine the tumor response to ZalypsisActivity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.Present and future evolution of advanced breast cancer therapy.Complexity of receptor tyrosine kinase signal processing.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Inhibition of both EGFR and IGF1R sensitized prostate cancer cells to radiation by synergistic suppression of DNA homologous recombination repairThree-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative OnTargeted polymeric nanoparticles for cancer gene therapy.Profile of erlotinib and its potential in the treatment of advanced ovarian carcinomaDocetaxel in the treatment of squamous cell carcinoma of the head and neckTargeting EGFR and PI3K pathways in ovarian cancer.Tumor-targeted delivery of siRNA by self-assembled nanoparticles.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaDesigner monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting.The paradigm of personalized therapy in oncology.Dual targeting strategies with bispecific antibodies.Novel targeted agents for the treatment of advanced breast cancer.MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death.Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma.Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1.Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.Surface engineering of gold nanoparticles for in vitro siRNA delivery.Dietary energy balance modulation of epithelial carcinogenesis: a role for IGF-1 receptor signaling and crosstalk.EGFR controls bone development by negatively regulating mTOR-signaling during osteoblast differentiation.
P2860
Q28074073-29FE8F5D-B22A-424D-85FB-9C91EC23D88BQ33622731-29C10CB7-F63F-4B54-A176-985300548369Q33842810-4074010F-CAAA-4315-A351-AF43C52B5745Q34274925-49686776-E004-4C18-B234-CF0D6D377E0BQ34361161-6DE22637-E2A7-4ABD-825F-5EA92A4EC2C2Q34704781-B3F61BE2-DFFF-4645-A315-F5C7C9B85BCAQ34946047-51B7FDE9-2490-4CDD-8D85-55C8664A823AQ36029760-E3844C89-1DAC-44EF-92D2-DC72E02401B6Q36416427-FD5615F4-3F72-49A1-861F-F56C4B84DEA9Q36880902-7240230E-F194-4AB4-B638-1090536C0F3CQ37052798-E24A91E4-CC68-4F6C-B316-159E4CFCAEABQ37214329-1C662ECF-961E-40E6-8EDE-077CEA42C338Q37338160-50E30525-3C9F-4628-8A09-E24DE82C8514Q37351498-7AD8F95C-C0AF-4137-AB59-92D81EFADEB2Q37430548-FFE108D0-C1BC-4757-BE2D-6407B1E95556Q37485865-0B2D51D3-EB82-4815-BCFD-268E3AA47CE5Q37639772-65F3688D-4AA0-4890-85C0-5AFEA60BBB1AQ37954671-353A7351-C36C-4D83-882F-978B5BB27378Q37997559-2E2F78B1-58CB-4B35-98A9-30A146EDFD0DQ38008723-F3270F7D-7060-45D7-B85E-33DCF1845369Q39413378-ABF174AC-B64D-4A81-9A49-B0C4536FE1F1Q39561256-2FE44F05-3455-463A-8152-09A127E041F8Q39756768-059AF1E4-316F-4D0F-971B-5ECA7163059FQ43141124-50F74535-8973-4D0D-8027-DA4E172839ECQ44645468-ED00FC27-0CBD-4D36-9BCE-9E0230688E07Q46376664-1C7B04D8-8775-46AC-99FD-E19226A1D152Q47105720-9CFC3CF4-E7C0-4AA6-B262-74A5FFE10C98Q50493805-8C77AD12-78C3-4C0D-8858-86ABEC3875A4Q54571481-B98EC66D-4D8B-4BD1-8D68-B45A548EBC98Q55230047-7BF86875-4E97-4EA5-ABFB-E698F16E831D
P2860
Growth factor receptor interplay and resistance in cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Growth factor receptor interplay and resistance in cancer.
@ast
Growth factor receptor interplay and resistance in cancer.
@en
type
label
Growth factor receptor interplay and resistance in cancer.
@ast
Growth factor receptor interplay and resistance in cancer.
@en
prefLabel
Growth factor receptor interplay and resistance in cancer.
@ast
Growth factor receptor interplay and resistance in cancer.
@en
P2093
P356
P1476
Growth factor receptor interplay and resistance in cancer.
@en
P2093
Denise Barrow
Helen E Jones
Iain R Hutcheson
Janice M Knowlden
Robert I Nicholson
P304
P356
10.1677/ERC.1.01275
P478
13 Suppl 1
P50
P577
2006-12-01T00:00:00Z